In COVID-19 clinical update #71, Daniel Griffin reviews updated school and child care guidance from CDC, transmission in schools, accuracy of lateral flow assays, update to J&J/Janssen vaccine EUA to include GBS, interim immunogenicity of Ad.26.CoV2.s, effectiveness of mRNA vaccines to prevent hospitalization, Bamlanivimab plus Etesevimab for mild or moderate disease, and a meta-analysis of ivermectin results.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

School and child care guidance (CDC)
Transmission in schools (CDC)
Accuracy of lateral flow diagnostics (Lancet)
GBS with Ad.26.CoV2.s vaccine (FDA)
Ad.26.CoV2.s interim immunogenicity (NEJM)
mRNA vaccine effectiveness to prevent hospitalization (medRxiv)
Bamlanivimab plus Etesevimab (NEJM)
Meta-analysis of ivermectin studies (Clin Inf Dis)
Letters read on TWiV 780
Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

TWiV 780: COVID-19 clinical update #71 with Dr. Daniel Griffin